P499: THE PHASE 1B OMNIVERSE TRIAL OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF RELAPSED/REFRACTORY OR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (TRIAL IN PROGRESS)

• A. H. Wei,
• H. E. Carraway,
• L. Taningco,
• E. Laille,
• J. Gong,
• T. Prebet,
• D. Lopes de Menezes,
• F. Ravandi

Affiliations

A. H. Wei

1 Department of Clinical Haematology, Alfred Hospital, and the Australian Centre for Blood Diseases, Monash University, Melbourne, Australia

H. E. Carraway

2 Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland

L. Taningco

3 Bristol Myers Squibb, Princeton

E. Laille

3 Bristol Myers Squibb, Princeton

J. Gong

3 Bristol Myers Squibb, Princeton

T. Prebet

3 Bristol Myers Squibb, Princeton

D. Lopes de Menezes

3 Bristol Myers Squibb, Princeton

F. Ravandi

4 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America